Literature DB >> 2550349

Expression of intermediate filaments in malignant fibrous histiocytomas.

T Hirose1, E Kudo, T Hasegawa, J Abe, K Hizawa.   

Abstract

The expression of intermediate filaments (IFs) in 34 malignant fibrous histiocytomas (MFHs) was studied immunohistochemically and ultrastructurally. Using the avidin-biotin-peroxidase method, positive reactions were detected as follows: for desmin in 12 tumors, for neurofilament in two tumors, for cytokeratin in one tumor, and for vimentin in 30 tumors. Desmin immunoreactivity was found in tumors of all four histologic subtypes and cytokeratin immunoreactivity was found in one tumor of the myxoid type. Because of the cross-reactivity of anti-neurofilament antibody with reactive histiocytes, the immunoreactivity for neurofilament seemed to be non-specific. Ultrastructurally, five of 13 tumors studied contained some tumor cells showing myofibroblastic or smooth muscle cell differentiation. A few tumor cells in one cytokeratin-positive tumor had tonofilaments in their cytoplasm. Desmin expression in some MFHs seemed to be due to myofibroblastic or smooth muscle cell differentiation of some tumor cells. Cytokeratin expression seemed to indicate epithelial differentiation in some MFHs. This varied expression of IFs in MFHs may reflect the heterogeneous nature of MFHs, and suggests that MFHs represent the final stages of dedifferentiation of several different types of sarcomas or, alternatively, represent forms of poorly differentiated sarcoma with the potential of developing into more differentiated sarcomas of heterogeneous origin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550349     DOI: 10.1016/0046-8177(89)90099-3

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma.

Authors:  P Dias; D M Parham; D N Shapiro; B L Webber; P J Houghton
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

2.  Cytoskeletal characteristics of myofibroblasts in benign neoplastic and reactive fibroblastic lesions.

Authors:  T Hasegawa; T Hirose; E Kudo; J Abe; K Hizawa
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 3.  A review of intermediate filament biology and their use in pathologic diagnosis.

Authors:  R B Nagle
Journal:  Mol Biol Rep       Date:  1994-01       Impact factor: 2.316

4.  Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas.

Authors:  C Gustmann; M Altmannsberger; M Osborn; H Griesser; A C Feller
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

5.  FU-3 monoclonal antibody: a specific marker for malignant fibrous histiocytoma? An analysis of 32 malignant soft tissue and bone sarcomas.

Authors:  M J Perez-Bacete; A Llombart-Bosch
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

6.  Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation.

Authors:  G Tallini; D M Parham; P Dias; C Cordon-Cardo; P J Houghton; J Rosai
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

7.  Morphological heterogeneity and phenotypical instability versus metastatic stability in the murine tumor model ER 15-P.

Authors:  G Edel; A Roessner; B Deneke; B Wörmann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Expression of smooth muscle markers in so called malignant fibrous histiocytomas.

Authors:  T Hasegawa; F Hasegawa; T Hirose; T Sano; Y Matsuno
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

Review 9.  Myofibrosarcoma.

Authors:  Cyril Fisher
Journal:  Virchows Arch       Date:  2004-06-02       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.